Study wrapper · #115
From evidence to practice: Identifying candidates for semaglutide in chronic atherosclerotic disease.
Editor's note
This is not an efficacy study but an eligibility-mapping exercise, and reading it correctly matters. The underlying evidence, that semaglutide reduced atherothrombotic events and cardiovascular mortality in coronary patients with and without diabetes, comes from the SELECT and SOUL randomized trials and is genuinely strong. What this paper adds is a real-world denominator: applying regulatory eligibility criteria to 12,430 patients in two Italian cardiology registries, the authors estimate that 54.3% (6,748) would potentially qualify for semaglutide, including 42.5% of non-diabetic patients (SELECT-like) and 97.9% of diabetic patients (SOUL-like). The finding is about scale of the eligible population, not about whether giving them the drug yields benefit, that inference rests on the trials. Caveats: registry populations reflect specific catchments and prescribing eras, eligibility is not the same as appropriateness or access, and cost/sustainability, which the authors flag, is left open. Useful for health-system planning; it says nothing new about how well the drug works.
Plain-language abstract
This study did not test whether semaglutide works, that was already shown in two large randomized trials (SELECT and SOUL), which found the drug lowered the combined risk of heart-attack-type events and death from heart causes in people with coronary artery disease, whether or not they had diabetes. Instead, this paper asked a practical question: in everyday cardiology practice, how many patients would actually qualify for the drug under the official eligibility rules based on those trials? The researchers looked at 12,430 patients in two Italian heart-disease registries. After excluding 623 for severe kidney problems or because they were already on a similar drug, they examined 11,807 patients. Among those without diabetes, 42.5% matched the profile of SELECT trial participants (overweight or obese with established heart disease). Among those with diabetes, 97.9% matched the SOUL profile (age 50 or older with cardiovascular disease). Overall, about 54% of all patients would potentially be eligible. The authors say this helps health systems estimate how many people might need this treatment and plan for its cost.